{"id":34698,"date":"2016-11-07T15:41:44","date_gmt":"2016-11-07T07:41:44","guid":{"rendered":"http:\/\/www.chinamoneynetwork.com\/?p=57348"},"modified":"2016-11-07T15:41:44","modified_gmt":"2016-11-07T07:41:44","slug":"sequoia-backed-betta-pharma-completes-106m-ipo-in-chinas-chinext-board","status":"publish","type":"post","link":"https:\/\/www.chinalegalblog.com\/en\/2016\/11\/07\/sequoia-backed-betta-pharma-completes-106m-ipo-in-chinas-chinext-board\/","title":{"rendered":"Sequoia-Backed Betta Pharma Completes $106M IPO In China's ChiNext Board"},"content":{"rendered":"<img width=\"477\" height=\"330\" src=\"http:\/\/www.chinamoneynetwork.com\/wp-content\/uploads\/healthcare-copy-7.jpg\" class=\"attachment-large size-large wp-post-image\" alt=\"healthcare-copy-7\" style=\"display: block; margin: auto; margin-bottom: 5px;\" srcset=\"http:\/\/www.chinamoneynetwork.com\/wp-content\/uploads\/healthcare-copy-7.jpg 477w, http:\/\/www.chinamoneynetwork.com\/wp-content\/uploads\/healthcare-copy-7-300x208.jpg 300w\" sizes=\"(max-width: 477px) 100vw, 477px\" \/>Betta Pharmaceuticals Co., Ltd., backed by Sequoia Capital China and other investors, has completed an initial public offering on the Shenzhen Stock Exchange's NASDAQ-style ChiNext Board, raising RMB720 million (US$106 million). The pharmaceutical company issued shares at RMB17.57 apiece, at a 22.99 price-to-earning ratio. The company's shares jumped 44% before their trading was halted after [&#8230;]<p><br>Visit <a href=\"http:\/\/www.chinamoneynetwork.com\/\" title=\"China Money Network\"><b>ChinaMoneyNetwork.com<\/b><\/a> for more daily finance news, including audio and video Internet podcasts covering important investment news and financial events in China. Follow us on Twitter <a href=\"http:\/\/www.twitter.com\/chinamoneypod\" title=\"Follow China Money Network on Twitter\">@chinamoneypod<\/a> subscribe to all episodes on <a href=\"http:\/\/www.itunes.com\/podcast?id=451002399\" title=\"Download and listen to China Money Podcast on iTunes\">iTunes<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"<p><img loading=\"lazy\" decoding=\"async\" width=\"477\" height=\"330\" src=\"http:\/\/www.chinamoneynetwork.com\/wp-content\/uploads\/healthcare-copy-7.jpg\" alt=\"healthcare-copy-7\">Betta Pharmaceuticals Co., Ltd., backed by Sequoia Capital China and other investors, has completed an initial public offering on the Shenzhen Stock Exchange's NASDAQ-style ChiNext Board, raising RMB720 million (US$106 million). The pharmaceutical company issued shares at RMB17.57 apiece, at a 22.99 price-to-earning ratio. The company's shares jumped 44% before their trading was halted after [&hellip;]<\/p>\n<p>Visit <a href=\"http:\/\/www.chinamoneynetwork.com\/\" title=\"China Money Network\"><b>ChinaMoneyNetwork.com<\/b><\/a> for more daily finance news, including audio and video Internet podcasts covering important investment news and financial events in China. Follow us on Twitter <a href=\"http:\/\/www.twitter.com\/chinamoneypod\" title=\"Follow China Money Network on Twitter\">@chinamoneypod<\/a> subscribe to all episodes on <a href=\"http:\/\/www.itunes.com\/podcast?id=451002399\" title=\"Download and listen to China Money Podcast on iTunes\">iTunes<\/a>.<\/p>\n","protected":false},"author":167,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[194,1623],"tags":[5436,7593,5256],"class_list":["post-34698","post","type-post","status-publish","format-standard","hentry","category-news-chinese-law","category-venture-capital","tag-exits","tag-fund-news","tag-healthcare"],"_links":{"self":[{"href":"https:\/\/www.chinalegalblog.com\/en\/wp-json\/wp\/v2\/posts\/34698"}],"collection":[{"href":"https:\/\/www.chinalegalblog.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.chinalegalblog.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.chinalegalblog.com\/en\/wp-json\/wp\/v2\/users\/167"}],"replies":[{"embeddable":true,"href":"https:\/\/www.chinalegalblog.com\/en\/wp-json\/wp\/v2\/comments?post=34698"}],"version-history":[{"count":1,"href":"https:\/\/www.chinalegalblog.com\/en\/wp-json\/wp\/v2\/posts\/34698\/revisions"}],"predecessor-version":[{"id":34699,"href":"https:\/\/www.chinalegalblog.com\/en\/wp-json\/wp\/v2\/posts\/34698\/revisions\/34699"}],"wp:attachment":[{"href":"https:\/\/www.chinalegalblog.com\/en\/wp-json\/wp\/v2\/media?parent=34698"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.chinalegalblog.com\/en\/wp-json\/wp\/v2\/categories?post=34698"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.chinalegalblog.com\/en\/wp-json\/wp\/v2\/tags?post=34698"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}